Chief Executive Officer
Graduate of Biotechnology at the University of Life Sciences in Poznań. Experienced professional in medicinal products, medical devices, supplements and plant protection products R&D at every stage - from planning and scientific advice through supervision to the closure and finalization of the project. A founder of several start-ups in the e-health industry and a member of the board and supervisory board of several R&D companies. Author of the publication „Change of the product development model as an opportunity for the Polish pharmaceutical industry” (in Polish). Member of the editorial committee of the book „Clinical Trials” (in Polish). Lecturer in postgraduate study programs.
Chief Financial Officer
Mr. Christopher Cherry has over 14 years of corporate accounting and audit experience. Mr. Cherry has extensive corporate experience and has held senior level positions for several public mining companies including Director, Chief Financial Officer, and Secretary. Mr. Cherry is a CPA having obtained the Chartered Accountant designation in February 2009 and the Certified General Accountant designation in 2004. In his former experience as an auditor, he held positions with KPMG and Davidson and Co. LLP in Vancouver, where he gained experience as an auditor for junior public companies, and an IPO specialist.
Beata Pajak, DSc, PhD, Eng
Chief Scientific Officer
Biotechnologist with experience in the field of medical biology, including oncology, virology, pathophysiology of neurodegenerative diseases and skeletal muscle physiology. Expert in the field of signal pathways, mechanisms of programmed cell death, chemo- and immuno-resistance of cancer cells. Head and team member in research and implementation projects. Author and co-author of publications and conference reports. Laureate of L'Oreal UNESCO "For Women and Science" and “Polityka” journal "Stay with us" scholarships, Ministry of Science and Higher Education Scholarship for Young Outstanding Scientists, 1st Award of the Hasco-Lek Foundation for the doctoral dissertation and Gedeon Richter company distinction “With a passion for the future”.
Mr. Novak is a 30-year veteran of the insurance and financial services industry, he is currently the General Agent of one of MassMutual’s largest agencies with $4.8 billion in assets under management. He previously served as general agent to MassMutual’s Rochester agency; co-general agent at The New England/Robinson Co. in Waterbury, Connecticut; and as an agent at the New York Life Insurance Company.
He is the co-founder of the Charter Oak Fund, Charter Oak’s charitable arm, which supports numerous local philanthropic causes and organizations; the 2019 GAMA International Hall of Fame Inductee; a board member of GAMA International, as well as of GAMA’s Executive Leadership Cabinet; an executive board member of The Kosciuszko Foundation; a board member at Quinnipiac University; Chairman of the Board of Quinnipiac university’s Central European Institute (CEI); and an adjunct member of the University of Warsaw Alumni Association.
Mr. Klemp has 34 years of experience in start-up and high-growth companies, the past 15 of which have been spent developing FDA-regulated dermatology therapy devices and topical compounds.
Mr. Klemp is the Founder of Moleculin Biotech, Inc. (Nasdaq: MBRX) since 2007 and has also served as its CEO. Mr. Klemp has also served as President and CEO of Zeno Corporation from 2004 to 2010, where he successfully developed and marketed a number of dermatology devices and drugs from concept through FDA approval. Mr. Klemp is also a Founder and Executive Chairman of Soliton, Inc. (Nasdaq: SOLY), a medical device company founded in 2012.
Previously, Mr. Klemp served as CEO and Chairman of Drypers Corporation, a publicly traded multinational consumer products company which he founded, from 1987 to 2000. At Drypers, Mr. Klemp developed growth strategies, orchestrated mergers and acquisitions, and grew the company from start-up to $400 million in annualized sales and to a #1 ranking on the INC 500. Notably, he has overseen nearly $750 million in public and private financings throughout his career.
Mr. Klemp is appointed as Director of the Company. He is a member of the Audit Committee. Mr. Klemp intends to be available on an as needed basis, but will attend a minimum of 4 board meetings per year for the Company. Mr. Klemp is not an employee of the Company. Mr. Klemp has not entered into any non-competition agreement with the Company.
Ms. Rzepczyk has over 15 years of experience working with junior resources companies, with a particular focus on accounting and finance. Ms. Rzepczyk has an extensive background in organizing and managing public companies, including the going public process. Ms. Rzepczyk has experience as Controller of First Merit Group and is the former Chief Financial Officer and a former Director of Cannex Capital Holdings Inc. (formerly, Arco Resources Corp.).
Ms. Rzepczyk is also fluent in Polish, which will assist the Company in its integration of WPD’s business.
Canadian Vice President of Legal, Corporate Secretary and Director
Mr. Corcoran has extensive legal and business experience and is currently a partner of a multi-disciplinary legal practice with an emphasis on property insurance and related litigation. Mr. Corcoran was formerly an associate at a large Vancouver based law firm. He obtained his Juris Doctor from Thompson Rivers University Law School in 2014 and holds an undergraduate degree from McGill University.